Avandia

Avandia (rosiglitazone maleate) is an oral antidiabetic agent belonging to the thiazolidinedione (TZD) class. It functions primarily as a selective agonist for peroxisome proliferator-activated receptor-gamma (PPAR-γ), a nuclear receptor that regulates gene expression involved in glucose and lipid metabolism. Developed by SmithKline Beecham (now GlaxoSmithKline), Avandia was approved by the U.S. Food and Drug Administration (FDA) in May 1999 for the management of type 2 diabetes mellitus (T2DM). Its clinical utility lies in improving glycemic control by enhancing insulin sensitivity in peripheral tissues—primarily adipose tissue, skeletal muscle, and the liver—thereby reducing hepatic glucose output and increasing peripheral glucose uptake.